Patient Scenario 1: Diagnosis and Risk Stratification of Clear-Cell RCC
Join Wenxin (Vincent) Xu, MD, and his team at Dana-Farber Cancer Institute as they explore strategies for diagnosing and stratifying renal cell carcinoma, reviewing a clinical scenarios and best practices in workup.
EP: 1.Patient Scenario 1: Diagnosis and Risk Stratification of Clear-Cell RCC
EP: 2.Frontline Combination Strategies in Patients With Clear-Cell RCC
EP: 3.Clear-Cell RCC: Impact of Risk Stratification and NCCN Guidelines on 1L Therapy
EP: 4.Multidisciplinary Care and Supplemental Therapy in Clear-Cell RCC
EP: 5.Patient Scenario 2: Second-Line Treatment Options in Clear-Cell RCC
EP: 6.Clear-Cell RCC: Best Practices in Patient Monitoring
EP: 7.TIVO-3: Tivozanib as Third- or Later-Line Therapy in Clear-Cell RCC
EP: 8.Tivozanib in Clear-Cell RCC: Adverse Event Management Strategies
EP: 9.Tivozanib in Clear-Cell RCC: Dosing Schedule and Adjustments to Therapy
EP: 10.Evolving Treatment Landscape of Clear-Cell Renal Cell Carcinoma
EP: 11.Key Takeaways on the Management of Clear-Cell RCC
EP: 12.Immunotherapy/TKI Combinations Yield Efficacy Benefit in RCC
Summary:
In this clinical scenario, a 68-year-old woman, SK, presented with fatigue, right upper quadrant discomfort, and an 8-cm right renal mass diagnosed as clear cell renal cell carcinoma (RCC). Following a right total nephrectomy, she opted for active surveillance due to low disease volume. Two years later, a CT scan revealed bilateral pulmonary nodules, confirming advanced clear cell RCC through a biopsy. Despite normal blood work and a Karnofsky score of 90%, systemic therapy was initiated. The first-line approach involved cabozantinib and nivolumab, combining a tyrosine kinase inhibitor with an immunotherapy regimen.
The clinical presentation aligns with common symptoms seen at clinics like Dana-Farber, where patients often exhibit fatigue, pain, weight loss, or other systemic symptoms leading to a renal cell carcinoma diagnosis. Diagnosis and staging involve imaging, commonly starting with a CT scan, and may progress to a biopsy or nephrectomy based on findings. Staging incorporates the TNM system, assessing tumor size, lymph node involvement, and distant metastasis.
The discussion extended to the International mRCC (metastatic RCC) Database Consortium risk criteria, categorizing patients into favorable, unfavorable, or poor risk disease based on factors like performance status, time from diagnosis to systemic therapy, and laboratory results. This risk assessment aids in predicting survival and guides oncologists in selecting appropriate first-line systemic therapy. The initiation of systemic therapy, in this case, cabozantinib and nivolumab, is influenced by the patient’s risk group. Landmark trials categorized patients into risk groups, demonstrating varying benefits from treatments. Identifying the patient’s risk group becomes crucial for prognostication and tailoring effective first-line systemic therapy.
This scenario highlights the complexity of managing clear cell RCC, emphasizing the importance of risk assessment in predicting outcomes and guiding treatment decisions. The integration of targeted therapies and immunotherapies in first-line regimens reflects evolving strategies in managing advanced renal cell carcinoma.
Summary is AI-generated and reviewed by Cancer Network editorial staff.
Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors
A 47-year-old woman with a history of drug-resistant epilepsy during childhood presented to the emergency department with sudden dyspnea and chest pain. Upon admission, her oxygen saturation was 88%.
Belzutifan Improves PFS Across Subgroups for Advanced ccRCC
July 12th 2024“In LITESPARK-005, PFS and response rates favored belzutifan vs everolimus across [several patient subgroups, including] IMDC risk, number of prior lines [of therapy], and number of prior VEGF TKIs, specifically,” said Laurence Albiges, MD, PhD.
